• {{ window.visitor.corporateClient.name }} Corporate solution {{ window.visitor.ipAccess.corporateClient.name }} {{ window.visitor.corporateClient.name }}

• Welcome to our Corporate client solution

  Here you can administrate your corporate solutions users.

• Welcome to your subscription for Life Science Nordic

• Welcome to our Corporate client solution

  Your IP is registered with the company mentioned above and provides access to Life Science Nordic.

• Manage corporate subscription {{company.name}}
• Click here to go to sign-up

Get access to all content on Life Science Nordic

No commitment or card information required

Already a subscriber? Log In

An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.

August 13, 2026 3:18 PM

U.S.‑based Definium Therapeutics is developing DT120, a medical low‑dose form of lysergide (LSD), as a potential oral treatment for several psychiatric conditions. In June, the company announced phase III data showing that the treatment significantly reduces symptoms of severe depression. Now the company is presenting another success, this time in generalized anxiety disorder (GAD).

BREAKING